Biomarkers of Barrett's esophagus.
Barrett's esophagus is the strongest risk for esophageal adenocarcinoma (EAC). Metaplasia in patients with BE may progress to dysplasia and then invasive carcinoma. Well-defined diagnostic, progressive, predictive, and prognostic biomarkers are needed to identify the presence of the disease, estimate the risk of malignant transformation, and predict the therapeutic outcome and survival of EAC patients. There are many predictive and prognostic markers that lack substantial validation, and do not allow stratification of patients with gastroesophageal reflux disease in clinical practice for outcome and effectiveness of therapy. In this short review we summarize the current knowledge regarding possible biomarkers, focusing on the pathophysiologic mechanisms to improve prognostic and therapeutic approaches.
Yasser Mahrous Fouad, Reem Yehia, Gastroenterology and Hepatology Unit, Tropical Medicine Department, Minia University, Minia 11432, Egypt.
Yasser Mahrous
YM
Fouad
Yasser Mahrous Fouad, Reem Yehia, Gastroenterology and Hepatology Unit, Tropical Medicine Department, Minia University, Minia 11432, Egypt.
Ibrahim
I
Mostafa
Yasser Mahrous Fouad, Reem Yehia, Gastroenterology and Hepatology Unit, Tropical Medicine Department, Minia University, Minia 11432, Egypt.
Reem
R
Yehia
Yasser Mahrous Fouad, Reem Yehia, Gastroenterology and Hepatology Unit, Tropical Medicine Department, Minia University, Minia 11432, Egypt.
Hisham
H
El-Khayat
Barrett’s esophagus; Biomarkers; Esophageal adenocarcinoma